SG11202109662YA - Compositions and methods for treating cancer - Google Patents
Compositions and methods for treating cancerInfo
- Publication number
- SG11202109662YA SG11202109662YA SG11202109662YA SG11202109662YA SG 11202109662Y A SG11202109662Y A SG 11202109662YA SG 11202109662Y A SG11202109662Y A SG 11202109662YA SG 11202109662Y A SG11202109662Y A SG 11202109662YA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- cancer
- alkyl
- hydrogen
- glucose
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819322P | 2019-03-15 | 2019-03-15 | |
| US201962904241P | 2019-09-23 | 2019-09-23 | |
| PCT/US2020/022743 WO2020190765A2 (en) | 2019-03-15 | 2020-03-13 | Compositions and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109662YA true SG11202109662YA (en) | 2021-10-28 |
Family
ID=72521289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109662Y SG11202109662YA (en) | 2019-03-15 | 2020-03-13 | Compositions and methods for treating cancer |
Country Status (17)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240017986A (ko) * | 2017-09-26 | 2024-02-08 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암 치료를 위한 조성물 및 방법 |
| KR102809395B1 (ko) | 2019-03-15 | 2025-05-16 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암을 치료하기 위한 조성물 및 방법 |
| US20240058340A1 (en) * | 2020-09-21 | 2024-02-22 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061299A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer |
| WO2022061201A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022155311A1 (en) * | 2021-01-14 | 2022-07-21 | The Regents Of The University Of California | Methods and systems for analysis of drug target engagement and treatment of cancer |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| US20240165132A1 (en) * | 2021-05-12 | 2024-05-23 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN113307799B (zh) * | 2021-05-21 | 2022-07-19 | 大连医科大学 | 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用 |
| CA3233057A1 (en) * | 2021-09-23 | 2023-03-30 | Erasca, Inc. | Egfr inhibitor polymorph forms |
| WO2023244639A1 (en) * | 2022-06-14 | 2023-12-21 | The Regents Of The University Of California | Methods of predicting cns cancer response to treatment with egfr inhibitors |
| US20260108524A1 (en) * | 2022-10-14 | 2026-04-23 | The Regents Of The University Of California | Egfr inhibitors for treating lung cancer |
| WO2024102177A1 (en) * | 2022-11-08 | 2024-05-16 | The Regents Of The University Of California | Combination therapies for the treatment of brain cancer |
| AU2024388187A1 (en) * | 2023-11-27 | 2026-06-18 | Katmai Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| KR100397792B1 (ko) * | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법 |
| CN1854130B (zh) | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | 喹唑啉衍生物、及其制法和药物组合物与用途 |
| WO2008046242A1 (fr) | 2006-10-16 | 2008-04-24 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations |
| EP2484678B1 (en) | 2009-09-28 | 2015-01-21 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors |
| ITPD20110091A1 (it) | 2011-03-24 | 2012-09-25 | Univ Padova | Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico. |
| CA3081443A1 (en) * | 2014-12-15 | 2016-06-23 | The Regents Of The University Of Michigan | Small molecule inhibitors of egfr and pi3k |
| WO2016123706A1 (en) * | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Novel fluorinated derivatives as egfr inhibitors useful for treating cancers |
| CN105017163A (zh) | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途 |
| US10473255B2 (en) | 2015-12-29 | 2019-11-12 | Ge-Hitachi Nuclear Energy Americas Llc | Reactor pressure vessel including pipe restraint device, and/or a pipe restraint device |
| CA3008312A1 (en) | 2016-01-06 | 2017-07-13 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as egfr inhibitors |
| CN106432202B (zh) | 2016-09-22 | 2019-04-02 | 郑州大学第一附属医院 | 喹唑啉类衍生物及其应用 |
| KR20240017986A (ko) * | 2017-09-26 | 2024-02-08 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암 치료를 위한 조성물 및 방법 |
| KR102809395B1 (ko) * | 2019-03-15 | 2025-05-16 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암을 치료하기 위한 조성물 및 방법 |
| US20240058340A1 (en) * | 2020-09-21 | 2024-02-22 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061201A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061299A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer |
| CA3233057A1 (en) * | 2021-09-23 | 2023-03-30 | Erasca, Inc. | Egfr inhibitor polymorph forms |
| WO2023244639A1 (en) * | 2022-06-14 | 2023-12-21 | The Regents Of The University Of California | Methods of predicting cns cancer response to treatment with egfr inhibitors |
-
2020
- 2020-03-13 KR KR1020217032873A patent/KR102809395B1/ko active Active
- 2020-03-13 WO PCT/US2020/022743 patent/WO2020190765A2/en not_active Ceased
- 2020-03-13 CR CR20210498A patent/CR20210498A/es unknown
- 2020-03-13 CA CA3133688A patent/CA3133688A1/en active Pending
- 2020-03-13 MX MX2021011272A patent/MX2021011272A/es unknown
- 2020-03-13 EP EP20773177.9A patent/EP3938354A4/en active Pending
- 2020-03-13 SG SG11202109662Y patent/SG11202109662YA/en unknown
- 2020-03-13 PH PH1/2021/552208A patent/PH12021552208A1/en unknown
- 2020-03-13 BR BR112021018295A patent/BR112021018295A2/pt unknown
- 2020-03-13 CN CN202210268803.XA patent/CN115215808B/zh active Active
- 2020-03-13 CN CN202080034742.XA patent/CN113811528A/zh active Pending
- 2020-03-13 AU AU2020241703A patent/AU2020241703B2/en active Active
- 2020-03-13 JP JP2021555445A patent/JP7474269B2/ja active Active
-
2021
- 2021-09-13 IL IL286350A patent/IL286350A/en unknown
- 2021-09-14 US US17/475,144 patent/US11377451B2/en active Active
- 2021-09-15 SA SA521430328A patent/SA521430328B1/ar unknown
- 2021-09-15 CL CL2021002409A patent/CL2021002409A1/es unknown
- 2021-10-11 CO CONC2021/0013496A patent/CO2021013496A2/es unknown
-
2022
- 2022-06-29 US US17/853,573 patent/US20230115366A1/en not_active Abandoned
-
2024
- 2024-04-12 JP JP2024064400A patent/JP7789832B2/ja active Active
- 2024-06-12 US US18/741,322 patent/US20250145634A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230115366A1 (en) | 2023-04-13 |
| CN115215808A (zh) | 2022-10-21 |
| KR20210151820A (ko) | 2021-12-14 |
| EP3938354A4 (en) | 2022-12-28 |
| IL286350A (en) | 2021-10-31 |
| BR112021018295A2 (pt) | 2021-11-23 |
| JP7789832B2 (ja) | 2025-12-22 |
| PH12021552208A1 (en) | 2022-05-30 |
| CR20210498A (es) | 2022-01-11 |
| CL2021002409A1 (es) | 2022-06-17 |
| US11377451B2 (en) | 2022-07-05 |
| AU2020241703B2 (en) | 2026-02-05 |
| JP7474269B2 (ja) | 2024-04-24 |
| JP2024102094A (ja) | 2024-07-30 |
| MX2021011272A (es) | 2021-10-01 |
| US20250145634A1 (en) | 2025-05-08 |
| WO2020190765A3 (en) | 2020-11-26 |
| EP3938354A2 (en) | 2022-01-19 |
| CN115215808B (zh) | 2025-04-18 |
| SA521430328B1 (ar) | 2024-03-28 |
| WO2020190765A2 (en) | 2020-09-24 |
| AU2020241703A1 (en) | 2021-10-14 |
| CN113811528A (zh) | 2021-12-17 |
| CO2021013496A2 (es) | 2022-01-17 |
| KR102809395B1 (ko) | 2025-05-16 |
| CA3133688A1 (en) | 2020-09-24 |
| US20220064177A1 (en) | 2022-03-03 |
| JP2022526266A (ja) | 2022-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11377451B2 (en) | Compositions and methods for treating cancer | |
| AU2023282187B2 (en) | Compositions and methods for treating cancer | |
| US20220062291A1 (en) | Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a) with reduced inhibitory activity targeted to the dopamine d2 receptor and accompanying toxicity | |
| US9205091B2 (en) | Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer | |
| US9040585B2 (en) | Small molecule antagonists of phosphatidylinositol-3,4,5-triphosphate (PIP3) and uses thereof | |
| EP3125901A1 (en) | New derivatives of cephalosporin for treating cancer | |
| Zhang et al. | Anti-cancer effects of bis-oxidized thiopyran derivatives on non-small cell lung cancer: rational design, synthesis, and activity evaluation | |
| JP7244511B2 (ja) | Ly6Kを阻害する化合物およびそれらを使用する方法 | |
| US20250082765A1 (en) | Molecules as anticancer agents for targeted treatment of breast and prostate cancer | |
| US20140045883A1 (en) | Ack1 kinase inhibition to treat triple negative breast cancer | |
| Pramanik | Development of hedgehog pathway inhibitors (HPI) in treatment of cancer | |
| KR100961688B1 (ko) | 다중약물내성 암세포에 유용한 항암제 | |
| CN108976235B (zh) | 一种喹唑啉酮类化合物及其用途 | |
| EA044668B1 (ru) | Композиции и способы для лечения рака | |
| HK40062377A (en) | Compositions and methods for treating cancer | |
| HK40083017A (en) | Compositions and methods for treating cancer | |
| KR20070025135A (ko) | 세프트리악손을 포함하는 stat3 활성 저해 활성을가지는 조성물 |